Develops novel therapies for autoimmune and inflammatory diseases using its proprietary drug discovery platform.
Coya Therapeutics, Inc. is a clinical-stage biotechnology company focused on advancing proprietary medicinal products designed to modulate the function of regulatory T cells (Tregs). The company's innovative pipeline includes therapeutic modalities such as Treg-enhancing biologics, Treg-derived exosomes, and autologous Treg cell therapy.
At the forefront of its development efforts is COYA 101, an autologous regulatory T-cell product candidate that has successfully completed a Phase 2a clinical trial for the treatment of Amyotrophic Lateral Sclerosis (ALS). Coya Therapeutics is also actively progressing product candidates through IND-enabling studies, including COYA 301, a Treg-enhancing biologic targeted for Frontotemporal Dementia treatment, and COYA 302, a biologic combination aimed at enhancing Treg function while reducing T effector function and activated macrophages in neurodegenerative and autoimmune diseases.
Additionally, the company is advancing COYA 201, an allogeneic Treg exosome product candidate in the preclinical stage for potential applications in neurodegenerative, autoimmune, and metabolic diseases. Furthermore, COYA 206, a discovery-stage antigen-directed Treg-derived exosome product candidate, underscores Coya Therapeutics' commitment to exploring cutting-edge therapies. Founded in 2020 and headquartered in Houston, Texas, Coya Therapeutics continues to expand its innovative portfolio aimed at addressing critical medical needs through advanced Treg-focused therapies.